BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 27, 2003
 |  BioCentury  |  Strategy

Dealing with Pfizer

Dealing with Pfizer

Pfizer Phase III deals
Seller/Buyer Compound Upfront & equity (% of total) Milestones Total R&D funding Sales upside Notes
Organon/PFE Asenapine (Neurology) $100 (27%) $270 $370 Undisclosed ...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >